Table 3 1-year survival probability comparison between cancer morphology (NENs vs non-NENs) and association between stage at diagnosis (localised vs metastasized) and cancer morphology for people diagnosed in England 2013–2015
Site | Total number of cases (stage I–IV) (n) | 1-year overall survival probability (%) | Association between NEN morphology and a diagnosis at stage 4 | |||||
|---|---|---|---|---|---|---|---|---|
NENs | Non-NENs | NENs (95% CI) | Non-NENs (95% CI) | OR (95% CI) (unadjusted) | p-value | OR (95% CI) (age-and sex-adjusted) | p-value | |
Bladder | 362 | 19,859 | 52.4 (47.4–57.1) | 74.9 (74.4–75.5) | 3.2 (2.6–4.0) | <0.000 | 3.2 (2.6–4.1) | <0.000 |
Breast | 51 | 117,052 | 82 (68.3–90.2) | 96.5 (96.4–96.6) | 3.9 (1.9–8.2) | <0.000 | 3.7 (1.8–7.7) | <0.000 |
Colon and caecum | 458 | 50,850 | 67.4 (62.8–71.6) | 82.6 (82.3–82.9) | 4 (3.3–4.8) | <0.000 | 3.8 (3.2–4.6) | <0.000 |
Female reproductive organs | 202 | 40,376 | 64.7 (57.4–71.1) | 89.5 (89.2–89.8) | 4.2 (3.2–5.7) | <0.000 | 5.2 (3.9–7) | <0.000 |
Oesophagus | 296 | 16,383 | 35.3 (29.6–41) | 51.6 (50.8–52.4) | 3.3 (2.6–4.2) | <0.000 | 3.6 (2.8–4.5) | <0.000 |
Pancreas | 838 | 8,936 | 77.6 (74.5–80.3) | 31 (29.7–31.5) | 0.6 (0.5–0.7) | <0.000 | 0.5 (0.5–0.7) | <0.000 |
Prostate | 52 | 98,963 | 21.1 (11.3–33.0) | 95.5 (95.4–95.6) | 41.7 (16.6–104.9) | <0.000 | 45.1 (17.8–113.9) | <0.000 |
Pulmonary | 1965 | 72,672 | 74.9 (72.9–76.8) | 47.2 (46.8–47.6) | 0.4 (0.4–0.5) | <0.000 | 0.4 (0.4–0.5) | <0.000 |
Rectum | 333 | 23,498 | 76.4 (71.4–80.7) | 86.8 (86.4–87.3) | 1.6 (1.3–2) | <0.000 | 1.5 (1.2–2.0) | <0.000 |
Skin (non-melanoma)a | 876 | 81,671 | 74.4 (71.6–77) | 92 (91.8–92.2) | ND | ND | ND | ND |
Small Intestine | 1164 | 1157 | 91.2 (89.4–92.7) | 61 (58.4–63.1) | 0.9 (0.8–1.1) | 0.314 | 0.9 (0.8–1.1) | 0.326 |
Stomach | 278 | 10,938 | 63.4 (57.3–68.9) | 48 (47.4–49.1) | 1.0 (0.8–1.3) | 0.24 | 0.9 (0.8–1.2) | 0.881 |
